Investing.com -- SELLAS Life Sciences stock fell 14% following the outcome of the interim analysis for its pivotal Phase 3 REGAL trial of GPS in Acute Myeloid Leukemia (AML). The Independent (LON: IOG ...
These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...
The New Republic on MSN8hOpinion
U.S. Attorney Vows to Target Anyone Who Tries to Stop Elon Musk’s DOGEThe Consumer Finance Protection Bureau stopped performing its oversight duties as soon as Trump appointed Scott Bessent as ...
Pennsylvania’s Department of Education denied an application for a teacherless, AI-led cyber charter school, to operate in ...
SELLAS Life Sciences Group announced that its Phase 3 REGAL trial of galinpepimut-S (GPS) for acute myeloid leukemia (AML) has successfully passed an interim analysis conducted by the Independent ...
NCLAT Delhi held that initiated proceedings before the Debts Recovery Tribunal does not preclude Financial Creditors to take remedy under Section 7, which is a special remedy provided under the IBC.
The city of Portland issued Zenith Energy a new Land Use Compatibility Statement (LUCS) on Monday morning, enabling the ...
The Karnataka Cabinet on Thursday decided to file an interim application before the Supreme ... is estimated at ₹3,011.66 crore in the form of TDR for acquiring 15 acres and 17.5 guntas of ...
Know Labs, Inc. (NYSE American: KNW), a pioneering leader in the development and application of radio frequency dielectric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback